Dihydrotestosterone, produced when the enzyme 5-alpha-reductase converts testosterone. It is a normal androgen, not a defect — the issue is how certain follicles respond to it.

Why does DHT grow a beard but shrink scalp hair?

Because the response is site-specific and genetically determined. The same hormone instructs different follicles differently — which is the paradox at the centre of pattern hair loss.

How do I read DHT-blocker marketing critically?

Ask which isoenzyme is addressed, whether the claim is oral or topical, and at what concentration. The article sets out a physician's checklist for exactly this.

DHT, Explained: The Hormone Behind Pattern Hair Loss — in Plain Language

August 17, 2026

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.

You've seen the term everywhere by now. On shampoo bottles. In supplement ads. In late-night search rabbit holes that started with “why is my part getting wider.” Three letters — DHT — invoked as the villain of every hair loss story, usually with no explanation beyond “block it.”

If you're going to spend years of your life and real money responding to this molecule, you deserve to actually understand it. Not the marketing version. The physiology.

As a physician who has spent nearly two decades formulating for thinning hair, I find that patients who understand the DHT pathway make calmer, smarter decisions. So this is my plain-language briefing: what DHT is, why it miniaturizes scalp hair while growing beard hair, how the two versions of its enzyme differ, why genes matter more than hormone levels, how women's pattern differs from men's, and how to read “DHT blocker” claims with a physician's skepticism.

What DHT Actually Is: One Enzyme, One Conversion

Start with testosterone. Everyone has it — men in larger amounts, women in smaller — a normal, essential hormone in both sexes.

In certain tissues, testosterone meets an enzyme called 5-alpha-reductase (I'll abbreviate it 5αR). The enzyme performs one chemical operation: it converts testosterone into dihydrotestosterone — DHT.

That single conversion matters enormously, because DHT is not just “more testosterone.” It is a substantially more potent androgen: it binds the androgen receptor — the docking site through which androgens issue instructions to cells — more tightly and more stably than testosterone does, so the same receptor delivers a much louder signal when DHT is the messenger (Azzouni et al., 2012). Where 5αR is abundant, androgen signaling is amplified. The scalp's hair follicles, unfortunately, are one of the places where that amplifier is installed.

In a genetically susceptible follicle, sustained DHT signaling triggers miniaturization: each successive growth cycle spends less time in anagen (the growing phase) and produces a slightly finer, shorter, less pigmented hair than the cycle before. Thick “terminal” hairs are gradually replaced by wispy, near-invisible “vellus” hairs. The follicle isn't dead — it's shrinking in slow motion. That is pattern hair loss, in one sentence.

The Great Paradox: Why DHT Grows Your Beard and Shrinks Your Scalp

Here is the question that puzzles almost everyone once they think about it: the same hormone that miniaturizes scalp follicles is what drives beard and body hair growth at puberty. How can one molecule grow hair in one place and destroy it four inches higher?

The answer is one of the most fascinating facts in hair biology: the response to DHT is not a property of the hormone. It is a property of the follicle.

Follicles in different body regions are developmentally different organs with different programming, and they retain their site-specific androgen response even when moved — the entire reason hair transplantation works: occipital (back-of-head) follicles relocated to the frontal scalp keep behaving like occipital follicles, indifferent to DHT (Randall, 2008). Beard follicles respond to androgens by growing bigger. Occipital follicles largely ignore them. Frontal and vertex follicles, in susceptible individuals, respond by miniaturizing — a paradox of androgen action in which the identical circulating hormone produces opposite effects depending on the follicle's intrinsic, genetically determined response program (Randall, 2008). The asymmetry lives in the receiver, not the broadcast.

This is why “my hormones are normal” and “my hair is thinning” are not contradictory statements. In most pattern hair loss, hormone levels are normal. It is the follicles' sensitivity that varies.

Type I and Type II: The Two Versions of the Enzyme

5-alpha-reductase is not a single enzyme but a small family. Two isoenzymes dominate the hair story:

Type II 5αR is the classic hair-loss enzyme — concentrated in the hair follicle (particularly the dermal papilla and outer root sheath), the prostate, and genital skin. Its central role was established by a famous natural experiment: individuals born with a genetic deficiency of Type II 5αR do not develop pattern baldness (Imperato-McGinley et al., 1974). No Type II enzyme, no pattern loss.
Type I 5αR predominates in the sebaceous (oil) glands and scalp skin, contributing to the local DHT environment surrounding the follicle rather than acting primarily inside it.

Both isoenzymes are present in and around human scalp follicles, and the balance differs by sex. In careful tissue studies, Sawaya and Price found that women's follicles carry roughly half the 5αR of men's, about 40% fewer androgen receptors — and far more protective aromatase in the frontal scalp (Sawaya & Price, 1997). The follicle's fate reflects the net arithmetic of enzymes and receptors, not any single number.

Why does the Type I/Type II distinction matter to you? Because interventions differ in which isoenzyme they engage — a detail that matters when you evaluate them, as we'll see below.

Genetics: The Sensitivity Dial You Were Born With

If DHT levels don't separate the thinning from the thick-haired, what does? Largely, inheritance.

Pattern hair loss is a polygenic trait — many genes, each nudging the odds. The best-established association involves the androgen receptor gene itself, on the X chromosome (the kernel of truth in the “mother's father” folklore, though susceptibility genes come from both parents). Variations in receptor sensitivity, receptor abundance, and local enzyme expression collectively set each follicle's response to a normal hormonal environment (Randall, 2008).

Two practical takeaways. First, a normal blood androgen panel does not rule out androgen-pattern hair loss — the biology happens at the receptor, in the follicle. Second, susceptibility is a dial, not a destiny switch: the pace of miniaturization is influenced by the total follicular environment — which is where intervention, of every kind, aims.

How Women's Pattern Differs From Men's

Men and women run the same underlying pathway with different hardware and different results.

Men — the Norwood pattern. Male pattern loss, mapped by the Norwood classification, is regional and frankly bald: the temples recede, the vertex thins, the zones merge, and affected areas can progress to smooth scalp (Norwood, 1975).

Women — the Ludwig pattern. Female pattern loss, classically mapped by Ludwig, looks entirely different: diffuse thinning over the crown and mid-scalp with preservation of the frontal hairline (Ludwig, 1977). Women rarely go bald in patches; instead the part widens, the ponytail shrinks, and scalp shows through hair that is still present but miniaturized.

Why the difference? Return to Sawaya and Price's arithmetic: women's follicles carry less 5αR and fewer androgen receptors, but women's frontal follicles carry substantially more aromatase — the enzyme that diverts testosterone away from the DHT pathway by converting it to estrogens. That aromatase reserve is one proposed reason the female hairline typically holds while density behind it fades (Sawaya & Price, 1997). It is also why hormonal transitions — postpartum, perimenopause, menopause — so often unmask thinning in women: when estrogen support falls, the androgen side of the ledger gains relative weight, without any androgen “excess” appearing on a lab report.

For the hormonal side of the story, see our Hormonal Hair Loss hub.

The Intervention Landscape, Stated Fairly

Now the question that brought you here: what can actually be done about DHT? I'll give you the honest map, category by category.

Finasteride — the pharmaceutical route. Finasteride is a prescription drug that inhibits 5αR (predominantly Type II) systemically — throughout the body — lowering DHT and slowing miniaturization, with meaningful efficacy established in large controlled trials in men (Kaufman et al., 1998). Stated just as fairly: it is a systemic hormonal intervention, its benefits require indefinite use, a subset of users report sexual and mood side effects, and — critically — it is off-limits for women who are or may become pregnant, because 5αR inhibition can interfere with the normal development of a male fetus. For premenopausal women, the primary pharmaceutical DHT drug is largely a non-option. That constraint, not marketing preference, is why non-drug approaches to hair concerns on this pathway are a serious scientific enterprise.

Minoxidil — effective, but not a DHT intervention. Worth naming to keep the map honest: topical minoxidil supports follicles through circulatory and growth-phase mechanisms; it does not act on the DHT pathway. The approaches are complementary — which is why everything in the MD® line works with or without minoxidil.

Plant-derived actives — the laboratory frontier. A number of botanical molecules are studied in laboratory models for effects on the follicle and the tissue environment around it. The one at the center of our formulation philosophy is verbascoside, the phenylethanoid glycoside we source from standardized lilac (Syringa vulgaris) stem cell culture — a molecule with a broad published research record (Alipieva et al., 2014). Its most directly relevant work is not on the enzyme — verbascoside makes no 5-alpha-reductase claim — but on the cells the enzyme's product acts upon: in laboratory studies on human dermal papilla cells, verbascoside induced proliferation, prevented testosterone-induced cell death, and reduced the release of pro-inflammatory signals — IL-1α and IL-6 from the papilla cells, IL-1β, TNF-α, and nitric oxide from macrophages (Wisuitiprot et al., 2022; the verbascoside in that study was sourced from Acanthus — the same molecule, a different plant). I choose those words deliberately. These are cell studies, not human trials — the study's own authors say clinical work is still needed — and no honest formulator should blur the two. What mechanism research gives you is rational design — an evidence-based reason a molecule belongs in a formula — without a drug's systemic exposure, and without a drug's claims. To say it plainly: our products are not drugs, and they do not do what finasteride does.

How to Read “DHT Blocker” Marketing — A Physician's Checklist

The phrase “DHT blocker” is doing an enormous amount of unearned work in this industry, and you should meet it with structured skepticism. My checklist:

“Blocker” is a claim about magnitude — demand context. A drug that inhibits the enzyme systemically and a botanical studied in laboratory models are profoundly different things sold with the same two words. Honest brands tell you which one you're reading about, unprompted.
Ask which isoenzyme. If a label invokes DHT but the company can say nothing about Type I versus Type II, the mechanism talk is decoration.
Ask what's actually in the bottle. A botanical name is not a dose. Wild-harvested extracts vary batch to batch; standardized sources (the reason we use lilac cell-culture verbascoside) specify the molecule at a verified level.
Beware borrowed evidence. Studies of one extract, at one concentration, in one model, do not transfer to a product that shares only an ingredient name.
Distrust timelines under three months. Hair cycles are slow. Any DHT-pathway story promising visible change in weeks contradicts its own biology.
Look for what regulators require. Non-drug products cannot lawfully claim to treat or cure hair loss — and responsible ones say so plainly. Cure-language on a supplement or cosmetic announces its own unreliability.

None of this skepticism means the pathway doesn't matter — it is among the best-established mechanisms in dermatology. It means the pathway deserves better than sloganeering. Understand the mechanism, demand standardization, and hold every product — including mine — to honest language.

The Bottom Line: Know the Pathway, Then Choose Deliberately

DHT is testosterone's amplified form, created by 5-alpha-reductase — an enzyme with two isoforms, both present around the human follicle. Whether a follicle thrives or miniaturizes under DHT is decided by its inherited programming: receptor sensitivity, enzyme balance, aromatase reserve. Men and women run the same pathway to visibly different patterns, and women face a starkly narrower pharmaceutical menu because the flagship 5αR drug is incompatible with potential pregnancy.

That is the honest landscape — and exactly why my formulation work has centered on the non-drug side of this space: standardized, laboratory-studied plant molecules like lilac-derived verbascoside, in a regimen that respects both the biology and the boundaries of honest claims. You now know enough to evaluate that choice — and every product that says “DHT” to you — on the merits.

Dr. Susan Lin's Clinical Perspective

“The most clarifying thing I tell patients about DHT is that it is not an invader — it is a normal hormone meeting a follicle that was born listening too closely. That reframe changes how you intervene: you are not purging a toxin, you are managing a signal, over years, in tissue you want to keep healthy. It's why I take the enzyme's two isoforms seriously, why I insist on standardized actives at verified levels rather than botanical folklore, and why I formulate drug-free and hormone-free — for the women I serve, many of whom could become pregnant or are already navigating hormonal transitions, adding a systemic hormonal drug to manage a local tissue signal is very often the wrong trade. Respect the pathway, work at the follicle, and be patient enough to let a slow organ respond.”

— Dr. Susan Lin, MD, Physician Formulator, MD HAIR

Mechanism Spotlight: Receptor Asymmetry — Why the Same Hormone Gives Opposite Orders

The strangest truth in androgen biology is that DHT carries no instructions of its own. It is a key, not a message: the message is written in the follicle that receives it. When DHT binds the androgen receptor in a beard follicle's dermal papilla, the papilla releases growth-supporting signals — the follicle enlarges. When the identical hormone binds the identical receptor in a susceptible frontal scalp follicle, the response program shifts toward growth-inhibiting signals, anagen shortens, and the follicle rebuilds itself slightly smaller each cycle (Randall, 2008). Sawaya and Price's tissue measurements gave the asymmetry its accounting: follicle fate tracks the local arithmetic of 5αR Types I and II, aromatase, and androgen receptor density — variables set by genetics, differing by scalp region and by sex (Sawaya & Price, 1997). Pattern hair loss, at bottom, is not a hormone problem. It is a hormone-response problem — which is why the follicle's local environment is where intervention logically aims.

MD HAIR Product Recommendation

MD® Hair Restoration System — The Concentrated 2-Step Peptide Protocol for Visible Thinning

If this article's biology describes what you're seeing in the mirror, the MD® Hair Restoration System is the regimen I designed for exactly this situation: MD® Follicle Activator (AM) + MD® Follicle Energizer (PM) — the concentrated 2-step peptide protocol for visible thinning. Morning and night, it delivers peptides and plant-based actives to the scalp — entirely drug-free and hormone-free, with no systemic hormonal exposure, which is precisely why it fits women for whom pharmaceutical 5αR inhibition is off the table. To be plain: it is a cosmetic regimen, not a drug — it does not inhibit 5-alpha-reductase and does not do what finasteride does; it is a drug-free option addressed to the same hair concern. It works with or without minoxidil, so it slots into whatever plan you've made with your physician. The system comes as a 3-month supply — matched to the biological timeline honest hair science requires. Physician-formulated, made in the USA in FDA-registered GMP facilities. Individual results vary.

And the internal arm of the same strategy. Because this article is about a signal generated in and around the follicle, I would add MD Nutri Hair™ to that system rather than choose between them. Its lilac verbascoside prevented testosterone-induced death of human dermal papilla cells in laboratory studies — the cells that read the androgen signal — and reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α in the same laboratory research — cell studies, not human trials. That is internal input plus the follicle's local environment, in one capsule a day, with no hormonal activity of its own. Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

Learn more about the full protocol at mdhair.com/pages/drug-free-hair-loss-treatment

References

Dr. Susan Lin, MD is the physician formulator behind MD HAIR, a line of drug-free, clinically informed hair-loss products by La Cañada Ventures, Inc. MD® products are manufactured in FDA-registered GMP facilities in the USA; they are not FDA approved and are not intended to diagnose, treat, cure, or prevent any disease. Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation. Individual results vary. This article is for educational purposes and does not constitute medical advice. Consult your physician for personalized guidance. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Explore more in our Verbascoside & Lilac Science series at mdhair.com/pages/verbascoside-hair-science